Table 1

Absolute number of viable B cells and T cells after L-744,832 treatment

Lymph Nodes
 Spleen
 Thymus
Untreated Wild-type
 B: 8.3 ± 4.4 × 105
 B: 3.8 ± 0.8 × 107
 B: 4.0 ± 3.2 × 105

T: 2.5 ± 1.2 × 106
 T: 2.5 ± 0.2 × 107
 T: 3.8 ± 1.9 × 107
L744 × 28 Wild-type
 B: 9.9 ± 2.8 × 105
 B: 1.4 ± 0.8 × 107
 B: 1.3 ± 0.6 × 105

T: 1.6 ± 0.9 × 106
 T: 9.0 ± 0.5 × 106
 T: 1.8 ± 0.7 × 107
Untreated Transplant
 B: 2.0 ± 2.5 × 107
 B: 1.8 ± 1.0 × 108
 B: 7.4 ± 5.9 × 107

T: 4.2 ± 3.9 × 106
 T: 4.0 ± 5.4 × 107
 T: 2.3 ± 2.1 × 107
L744 × 28 Transplant
 B: 2.3 ± 0.8 × 105
 B: 7.6 ± 2.9 × 106
 B: 9.4 ± 6.6 × 104

T: 4.8 ± 1.3 × 105
 T: 5.6 ± 2.4 × 106
 T: 9.2 ± 0.8 × 105
L744 × 7 Transplant
 B: 2.9 ± 0.7 × 105
 B: 1.0 ± 0.4 × 107
 B: 5.9 ± 1.9 × 105

T: 5.7 ± 1.2 × 105
 T: 6.5 ± 3.2 × 106
 T: 9.2 ± 1.9 × 105

The number of viable B cells and T cells is shown for cells isolated from either the lymph nodes, spleen, or thymus of mice. The mice are either C57BL/6 (Wild-type) or C57BL/6 transplanted with tumor cells from transgenic mice 28 days earlier (Transplant). The mice were left untreated or treated with L-744,832 for 28 days (L744 × 28) or for the final 7 days (L744 × 7). Total cell number was measured with a Coulter Counter, corrected for cell viability by 7AAD staining, and then multiplied by the relative number of B or T cells determined by B220 or Thy-1 staining, respectively. Data are from the same experiment as shown in Figure 4.

Field et al. Molecular Cancer 2008 7:39   doi:10.1186/1476-4598-7-39